PyrAmes Inc

PyrAmes Inc develops innovative non-invasive, continuous blood pressure monitoring solutions for patients across all age groups. The company specializes in wireless, calibration-free platforms designed to eliminate the need for invasive arterial lines and improve BP measurement accuracy in critical care settings. Product platforms include: - Boppli®: FDA 510(k)-cleared continuous non-invasive BP monitoring for neonatal and pediatric patients in NICU/PICU environments. Clinical evidence published in peer-reviewed journal Neonatology demonstrates accuracy comparable to arterial lines with superior usability and safety profile. - Bosimi®: Continuous non-invasive BP monitoring system for adult inpatient and emergency department care, enabling real-time hemodynamic assessment without invasive instrumentation. - Bosimi@Home™: Home-based platform for BP diagnostics, treatment validation, and medical management, supporting chronic disease monitoring and hypertension control in ambulatory settings. PyrAmes addresses significant clinical gaps: over 50% of NICU admissions could benefit from continuous BP monitoring but currently receive only intermittent cuff measurements or invasive arterial lines due to cost and safety concerns. In adults, hypertension affects 50% of the US population and contributes to 7.6 million deaths annually worldwide, creating demand for non-invasive continuous monitoring solutions. The company holds FDA 510(k) clearance for Boppli, FDA Breakthrough Device Designation, and recognition from the American Heart Association and National Institutes of Health (NIH RADx Tech Maternal Health Challenge). PyrAmes is a founding member of the CDC National Hypertension Control Roundtable. The technology enables early detection of hemodynamic instability in vulnerable populations including preterm infants and hypertensive adults.